Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$106.86M
Enterprise ValueAU$71.94M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding929,211,100
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$20.86M
Bulls Say, Bears Say
Bulls Say
Exclusive U.S. Distribution AgreementA guaranteed minimum USD 317M, six‑year U.S. distribution agreement provides durable multi-year revenue visibility and market access, materially de‑risking early commercial execution. This structural contract should support scaling, inventory planning and investor confidence across the PHASE term.
Medicare/MAC Reimbursement SecuredCMS reimbursement at USD 41.38 per test and agreement from seven MACs materially improves the economics for physician offices and payor coverage. This structural reimbursement reduces a key adoption barrier and supports sustained clinical demand and predictable per‑test pricing over time.
Improved Cash Generation And Nondilutive FundingTurning operating cash flow slightly positive and securing BARDA and trial funding reduces near‑term cash burn and dilutive financing need. Nondilutive grants and receipts provide runway for clinical work and initial commercialization, strengthening the durability of the funding mix.
Bears Say
Reliance On CLIA Waiver ApprovalThe commercial case and the PHASE guarantee activation depend on CLIA‑waiver approval. This regulatory contingency is a durable execution risk: without the waiver the company cannot fully access in‑office testing volumes, slowing revenue realization and capital payback over the contract life.
High Leverage And Weak Balance SheetA debt/equity ratio near 1.13 and low equity ratio constrain financial flexibility and raise refinancing risk when scaling commercial operations. Higher leverage increases interest exposure and can force dilutive or costly capital raises when funding manufacturing capacity or working capital for multi‑year contracts.
Persistent Unprofitability And Cash Flow PressuresChronic negative operating and free cash flow historically indicate structural cash generation weakness. Even with recent improvement, continuing adjusted EBITDA losses and upcoming manufacturing/scale investments imply ongoing cash needs, pressuring margins and requiring durable funding or strategic tradeoffs.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.03 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$106.86M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 91 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 929,211,100 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:LDX Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$119.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-164.12%
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---